Vident Advisory’s Biogen BIIB Stock Holding History

Vident Advisory’s Portfolio BIIB Stock Details BIIB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$1.02M	Sell	4,698 -403	-8%	-$77.1K	0.01%	961
2026 Q1	$935K	Buy	5,101 +896	+21%	+$165K	0.01%	909
2025 Q4	$740K	Sell	4,205 -792	-16%	-$129K	0.01%	949
2025 Q3	$700K	Sell	4,997 -67	-1%	-$9.06K	0.01%	1009
2025 Q2	$636K	Sell	5,064 -1,766	-26%	-$220K	0.01%	923
2025 Q1	$935K	Buy	6,830 +5,444	+393%	+$778K	0.01%	753
2024 Q4	$212K	Buy	1,386 +166	+14%	+$28K	﹤0.01%	1327
2024 Q3	$237K	Sell	1,220 -504	-29%	-$105K	0.01%	1223
2024 Q2	$400K	Sell	1,724 -668	-28%	-$145K	0.01%	1010
2024 Q1	$516K	Sell	2,392 -6,642	-74%	-$1.56M	0.01%	812
2023 Q4	$2.34M	Buy	9,034 +2,969	+49%	+$729K	0.06%	338
2023 Q3	$1.56M	Buy	+6,065	New	+$1.62M	0.05%	378

Other funds holding BIIB

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Norges Bank Oslo, Norway $1T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Vident Advisory's BIIB Position: Q2 2026 in Review

Vident Advisory reduced its Biogen (BIIB) stake by 7.9% in Q2 2026, selling an estimated $77.1K and leaving 4,698 shares worth $1.02M. The position accounts for 0.01% of the portfolio, ranked #961.

Vident Advisory first reported a position in BIIB in Q3 2023 and has held it in 12 quarters since. The position peaked at $2.34M in Q4 2023. 1,046 funds tracked by Wall St. Rank hold BIIB as of Q2 2026.

Vident Advisory held 4,698 shares of Biogen worth $1.02M as of Q2 2026.
Vident Advisory sold 403 Biogen shares in Q2 2026, an estimated $77.1K.
Biogen made up 0.01% of Vident Advisory's portfolio in Q2 2026, its #961 holding.
Vident Advisory first reported a position in Biogen in Q3 2023 and has held it in 12 quarters since.
Vident Advisory's Biogen position peaked at $2.34M in Q4 2023.
1,046 funds tracked by Wall St. Rank held Biogen as of Q2 2026.

Based on Vident Advisory's 13F filing for Q2 2026, filed 12 Aug 2026.